All In Biotech

Drug Trial Radar · NCT04126681

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

A Phase 2, Randomized, Open Label, Pivotal Study to Evaluate the Efficacy and Safety of HQP1351 in CML CP Patients Who Are Resistant and/or Intolerant to First- and Second-Generation Tyrosine Kinase Inhibitors

Last checked: Nov 20, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". Randomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144

Actual

Start

Oct 21, 2019

Primary completion

Aug 1, 2024

Study completion Aug 1, 2024

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
Collaborators
HealthQuest Pharma Inc.
First posted
Oct 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors. The efficacy of HQP1351 is determined by evaluating the subjects' event free survival (EFS).

Conditions

  • Chronic Myeloid Leukemia, Chronic Phase

Interventions

  • HQP1351Drug

    HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I

  • Hydroxyurea or Interferon-based therapyDrug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.

  • HomoharringtonineDrug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.

  • Imatinib, Dasatinib or NilotinibDrug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event free survival (EFS)Time frame: By the end of Cycle 24 (each cycle is 28 days)

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Gongdong, China

  • Nanfang hospital of southern medical university

    Guangzhou, Guangdong, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

  • The First affiliated hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Henan Provincial Oncology Hospital

    Zhengzhou, Henan, China

  • Henan Provincial people's Hospital

    Zhengzhou, Henan, China

  • Tongji Hospital medical college Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Union Hospital medical college Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First affiliated hospital of Nanchang University

    Nanchang, Jiangxi, China

  • First Hospital of Jilin University

    Changchun, Jilin, China

  • The Affiliated hospital of Qingdao University

    Qingdao, Shandong, China

  • Qilu hospital of Shandong University

    Jinan, Shangdong, China

  • Ruijing Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Blood Diseases Hospital Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine(hematology dept)

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine(HSCTdept)

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.